CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of cancer
3.4.1.2. Increase in demand of ideal therapeutics for treatment
3.4.1.3. Rise in awareness regarding T-cell therapy
3.4.2. Restraints
3.4.2.1. High cost of T-cell therapies
3.4.2.2. Strict government regulation for approval of drugs
3.4.3. Opportunities
3.4.3.1. Increase in R&D activities to develop T-cell therapeutics
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: T-CELL THERAPY MARKET, BY THERAPY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. CAR T-Cell therapy
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. CAR T-Cell therapy T-Cell therapy Market by Product Type
4.3. T-Cell Receptor (TCR)-Based
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: T-CELL THERAPY MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Lymphoma
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Acute Lymphocytic Leukemia
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: T-CELL THERAPY MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Cancer Treatment Centers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: T-CELL THERAPY MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Therapy Type
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Therapy Type
7.2.5.1.3. Market size and forecast, by Indication
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Therapy Type
7.2.5.2.3. Market size and forecast, by Indication
7.2.5.2.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Therapy Type
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Therapy Type
7.3.5.1.3. Market size and forecast, by Indication
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Therapy Type
7.3.5.2.3. Market size and forecast, by Indication
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Therapy Type
7.3.5.3.3. Market size and forecast, by Indication
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Rest of Europe
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Therapy Type
7.3.5.4.3. Market size and forecast, by Indication
7.3.5.4.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Therapy Type
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Therapy Type
7.4.5.1.3. Market size and forecast, by Indication
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Therapy Type
7.4.5.2.3. Market size and forecast, by Indication
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. Rest of Asia-Pacific
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Therapy Type
7.4.5.3.3. Market size and forecast, by Indication
7.4.5.3.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Therapy Type
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Latin America
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Therapy Type
7.5.5.1.3. Market size and forecast, by Indication
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Middle East And Africa
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Therapy Type
7.5.5.2.3. Market size and forecast, by Indication
7.5.5.2.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Novartis AG
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Autolus Therapeutics
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Caribou Biosciences, Inc
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Gilead Sciences, Inc.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Immunocore Ltd.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Celyad Oncology
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Key strategic moves and developments
9.7. Cartesian Therapeutics, Inc.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. Johnson & Johnson
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Bristol-Myers Squibb Company
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Cellectis, Inc.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
TABLE 01. GLOBAL T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 02. T-CELL THERAPY MARKET FOR CAR T-CELL THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL CAR T-CELL THERAPY T-CELL THERAPY MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 04. T-CELL THERAPY MARKET FOR T-CELL RECEPTOR (TCR)-BASED, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 06. T-CELL THERAPY MARKET FOR LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 07. T-CELL THERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2022-2032 ($MILLION)
TABLE 08. T-CELL THERAPY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 10. T-CELL THERAPY MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. T-CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. T-CELL THERAPY MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 18. U.S. T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 19. U.S. T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 20. CANADA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 21. CANADA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 22. CANADA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. EUROPE T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 24. EUROPE T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 25. EUROPE T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. EUROPE T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 27. GERMANY T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 28. GERMANY T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 29. GERMANY T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 30. FRANCE T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 31. FRANCE T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 32. FRANCE T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. UK T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 34. UK T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 35. UK T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. REST OF EUROPE T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 37. REST OF EUROPE T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 38. REST OF EUROPE T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. ASIA-PACIFIC T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 40. ASIA-PACIFIC T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 41. ASIA-PACIFIC T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 42. ASIA-PACIFIC T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 43. JAPAN T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 44. JAPAN T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 45. JAPAN T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 46. CHINA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 47. CHINA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 48. CHINA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 50. REST OF ASIA-PACIFIC T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 51. REST OF ASIA-PACIFIC T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 52. LAMEA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 53. LAMEA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 54. LAMEA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 55. LAMEA T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 56. LATIN AMERICA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 57. LATIN AMERICA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 58. LATIN AMERICA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 59. MIDDLE EAST AND AFRICA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 60. MIDDLE EAST AND AFRICA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 61. MIDDLE EAST AND AFRICA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 62. NOVARTIS AG: KEY EXECUTIVES
TABLE 63. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 64. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 65. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 66. AUTOLUS THERAPEUTICS: KEY EXECUTIVES
TABLE 67. AUTOLUS THERAPEUTICS: COMPANY SNAPSHOT
TABLE 68. AUTOLUS THERAPEUTICS: PRODUCT SEGMENTS
TABLE 69. AUTOLUS THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 70. AUTOLUS THERAPEUTICS: KEY STRATERGIES
TABLE 71. CARIBOU BIOSCIENCES, INC: KEY EXECUTIVES
TABLE 72. CARIBOU BIOSCIENCES, INC: COMPANY SNAPSHOT
TABLE 73. CARIBOU BIOSCIENCES, INC: PRODUCT SEGMENTS
TABLE 74. CARIBOU BIOSCIENCES, INC: PRODUCT PORTFOLIO
TABLE 75. CARIBOU BIOSCIENCES, INC: KEY STRATERGIES
TABLE 76. GILEAD SCIENCES, INC.: KEY EXECUTIVES
TABLE 77. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 78. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
TABLE 79. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 80. GILEAD SCIENCES, INC.: KEY STRATERGIES
TABLE 81. IMMUNOCORE LTD.: KEY EXECUTIVES
TABLE 82. IMMUNOCORE LTD.: COMPANY SNAPSHOT
TABLE 83. IMMUNOCORE LTD.: PRODUCT SEGMENTS
TABLE 84. IMMUNOCORE LTD.: PRODUCT PORTFOLIO
TABLE 85. IMMUNOCORE LTD.: KEY STRATERGIES
TABLE 86. CELYAD ONCOLOGY: KEY EXECUTIVES
TABLE 87. CELYAD ONCOLOGY: COMPANY SNAPSHOT
TABLE 88. CELYAD ONCOLOGY: PRODUCT SEGMENTS
TABLE 89. CELYAD ONCOLOGY: PRODUCT PORTFOLIO
TABLE 90. CELYAD ONCOLOGY: KEY STRATERGIES
TABLE 91. CARTESIAN THERAPEUTICS, INC.: KEY EXECUTIVES
TABLE 92. CARTESIAN THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 93. CARTESIAN THERAPEUTICS, INC.: PRODUCT SEGMENTS
TABLE 94. CARTESIAN THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 95. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 96. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 97. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 98. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 99. JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 100. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 101. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 102. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 103. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 104. CELLECTIS, INC.: KEY EXECUTIVES
TABLE 105. CELLECTIS, INC.: COMPANY SNAPSHOT
TABLE 106. CELLECTIS, INC.: PRODUCT SEGMENTS
TABLE 107. CELLECTIS, INC.: PRODUCT PORTFOLIO
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
